Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: A pilot study

Pediatric Allergy and Immunology

Volumn 12, Issue 3, 2001, Pages 154-158

  Pei, Ann Yuk Sau ^a,c   Chan, Henry Hin Lee ^a   Leung, Ting Fan ^b  

^a Department of Paediatrics ^*  (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atopic dermatitis; Children; Cysteinyl leukotriene 1 receptor antagonist; T helper cell imbalance

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO;

ADOLESCENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILD CARE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ACETATES; ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADOLESCENT; CHILD; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; PILOT PROJECTS; QUINOLINES;

EID: 0034944450     PISSN: 09056157     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3038.2001.012003154.x     Document Type: Article

References (28)

1. Pathogenesis of atopic eczema
2. Immune dysregulation in atopic eczema
3. Immunoglobulin E binding structures on antigen-presenting cells present in skin and blood
4. Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptor
5. Monteleukast for chronic asthma in 6-14 year old children: A randomized, double-blind trial
6. Pharmacotherapy of asthma in children, with special reference to leukotriene receptor antagonists
7. Asthma therapy with agents preventing leukotriene synthesis or action
8. Use of leukotriene antagonists in childhood asthma
9. Monteleukast, a leukotriene receptor antagonist decreasing the concentration of leukotrienes in the respiratory tract of children with persistent asthma
10. Asthma treatment: Antileukotriene drugs
11. Treatment of asthma with drugs modifying the leukotriene pathway
12. Successful treatment of chronic urticaria with leukotriene antagonists
13. Antileukotrienes in chronic urticaria
14. Monteleukast
15. Diagnostic features of atopic dermatitis
16. The Children's Dermatology Life Quality Index (CDLQI): Initial validation and practical use
17. Leukotrienes: Lipid bio-effectors of inflammatory reactions
18. Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis
19. Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema
20. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects
21. Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatosis
22. Generation of leukotrienes from normal epidermis and their demonstration in cutaneous disease
23. Eicosanoids in skin of patients with atopic dermatitis: Prostaglandin E2 and leukotriene B4 are present in biologically active concentrations
24. Leukotrienes in atopic eczema
25. Lipid mediators of hypersensitivity and inflammation
26. Leukotriene B4 and C4 generation by blood leukocytes after ex vivo stimulation by Ca-ionophore and opsonized zymosan in children with atopic dermatitis
27. The effect of the oral leukotriene antagonist, ICI 204,219, on leukotriene D4 and histamine-induced cutaneous vascular reactions in man
28. The Nottingham Eczema Severity Score: Preliminary refinement of the Rajka and Langeland grading